anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Review of experience to date suggests that a subgroup of older patients with associated severe illness may tolerate diarrhea less well. When clindamycin is indicated in these patients, they should be carefully monitored for change in bowel frequency. Clindamycin palmitate hydrochloride for oral solution should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis. Clindamycin palmitate hydrochloride for oral solution should be prescribed with caution in atopic individuals. 

Indicated surgical procedures should be performed in conjunction with antibiotic therapy. 

The use of clindamycin palmitate hydrochloride for oral solution occasionally results in overgrowth of nonsusceptible organisms-particularly yeasts. Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation.

Clindamycin dosage modification may not be necessary in patients with renal disease. In patients with moderate to severe liver disease, prolongation of clindamycin half-life has been found. However, it was postulated from studies that when given every eight hours, accumulation should rarely occur. Therefore, dosage modification in patients with liver disease may not be necessary. However, periodic liver enzyme determinations should be made when treating patients with severe liver disease.

Prescribing clindamycin palmitate hydrochloride for oral solution in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
INTRODUCTION: A high frequency of single nucleotide somatic mutations in the placenta has been recently described, but its relationship to placental dysfunction is unknown.
METHODS: We performed a pilot case-control study using paired fetal, maternal, and placental samples collected from healthy live birth controls (n = 10), live births with fetal growth restriction (FGR) due to placental insufficiency (n = 7), and stillbirths with FGR and placental insufficiency (n = 11). We quantified single nucleotide and structural somatic variants using bulk whole genome sequencing (30-60X coverage) in four biopsies from each placenta. We also assessed their association with clinical and histological evidence of placental dysfunction.
RESULTS: Seventeen pregnancies had sufficiently high-quality placental, fetal, and maternal DNA for analysis. Each placenta had a median of 473 variants (range 111-870), with 95 % arising in just one biopsy within each placenta. In controls, live births with FGR, and stillbirths, the median variant counts per placenta were 514 (IQR 381-779), 582 (450-735), and 338 (245-441), respectively. After adjusting for depth of sequencing coverage and gestational age at birth, the somatic mutation burden was similar between groups (FGR live births vs. controls, adjusted diff. 59, 95 % CI -218 to +336; stillbirths vs controls, adjusted diff. -34, -351 to +419), and with no association with placental dysfunction (p = 0.7).
DISCUSSION: We confirmed the high prevalence of somatic mutation in the human placenta and conclude that the placenta is highly clonal. We were not able to identify any relationship between somatic mutation burden and clinical or histologic placental insufficiency.
An apparatus for processing an imaging feed from an imaging device (i.e. camera) 1014, comprising an image transformation device and communication interface 1004, wherein only a transformed imaging feed is communicated beyond the communication interface to a further device 2000. The imaging feed may not be recorded prior to being received by the image transformation device. Also disclosed is an apparatus comprising a communication interface and means 1016 for authorising an entity to control the imaging feed before it is communicated to a further device. Control of the imaging feed may comprise the ability to view or edit the imaging feed. Also disclosed is an apparatus comprising a processor 1002 for extracting a region of an imaging feed and replacing the region with a corresponding region of an alternative imaging feed to generate a transformed imaging feed. The alternative imaging feed may be a copy of the imaging feed to which a blurring filter has been applied. The region may be user-defined using a user-interface 1010. Also disclosed are respective methods of processing imaging feeds from imaging devices.
NEW MATERIAL:The 8-(3-t-butylamino-2-hydroxypropoxy)-isocoumarine of formulaI(R is H, alkyl, alkenyl, alkoxy or nitro) and its pharmacologically nontoxic salt. EXAMPLE:8-Hydroxy-4-carbomethyoxy-isocoumarine. USE:Useful as a hypotensor and antiarrhythmic agent. There is no endogenous sympathetic stimulation activity. The agent has antagonistic activity against the arrythmia induced by adrenarin, and is useful for the prevnetion and remedy of circulatory diseases and arrhythmia. PROCESS:The compound of formulaIcan be prepared by reacting the 8-hydroxyisocoumarine compound of formula II with epihalohydrin in the presence of an accelerator such as sodium carbonate in an organic polar solvent, and reacting the resultant 8-(2,3-epoxypropoxy)-isocoumarine derivtive of formula III with tert- butylamine.
PURPOSE:To separate the titled novel substance effective to suppress the isolation of thrombocyte serotonin, by culturing a microbial strain belonging to Nocardiopsis genus. CONSTITUTION:A microbial strain belonging to Nocardiopsis genus and capable of producing KS-290 II i-2, e.g. Nocardiopsis sp. K290 (FERM-BP 696) is cultured in a medium under aeration and agitation, using a cultivation method and medium sued in conventional cultivation of actinomycetes. After removing the microbial cells from the medium by filtration, centrifugal separation, chromatography, etc., the objective KS-290 II i-2 is separated from the medium. The novel substance is white powder having a melting point of 240-245 deg.C, soluble easily in methanol and ethanol, insoluble in water, and having the activity to suppress the isolation of thrombocyte serotonin.
A stabilized bioadhesive composition containing an alkaline labile drug and a method for its preparation are provided. In one aspect, the composition is a hot-melt extruded (HME) composition comprising a preformed excipient mixture comprising an acidic component and an alkaline thermoplastic matrix-forming material, e.g. polymer. The excipient mixture is formed before blending with an alkaline labile drug. The blend is then hot-melt extruded to form the HME composition. By so doing, the acidic component is able to neutralize or render moderately acidic the excipient mixture. This particular process has been shown to substantially reduce the degradation of an alkaline labile drug during hot-melt extrusion. The excipient mixture softens or melts during hot-melt extrusion. It can dissolve or not dissolve drug-containing particles during extrusion. Various functional excipients can be included in the carrier system to improve process performance and/or improve the chemical or physical properties of the HME composition.
Patients with serum anti-Xa level \< 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours who then receive enoxaparin 40 mg every 12 hours. If repeat steady state trough anti-Xa is subtherapeutic, dose will be increased to enoxaparin 50 mg every 12 hours.
PURPOSE: A method of masking the bitter taste of sunblock is provided to remove the bitter taste by letting hexyl methoxycinnamate, butyl Methoxydibenzoylmethane, bis-ethylhexyloxy phenol methoxy phenyl triazine, and octocrylene be manufactured on the fat of a cosmetic composition. CONSTITUTION: A method of masking the bitter taste of a sunblock comprises the following steps. Add just enough of at least one sense tasting agent and just enough of at least a second sense tasting agent into the cosmetic composition. The first sense of the tasting agent is selected from a sweetener. The second sense of the tasting agent is selected from a group comprised of a sensuousness enhancer and an aroma. The sunblock comprises benzophenone-4, and 2-phenylbenzimidazole-5-sulfonic acid, methylenebis-benzotriazolyl tetramethylbutyl phenol or is an organic UV-blocking agent as a compound of these. The organic UV-sunblock is selected from a group comprised of sucrose, glucose, floc toss, acetic syulpalm K, aspartame, cyclam acid, sodium, potassium, calcium salt, isomalt, saccharin, sodium, potassium, calcium salt, sucralose, alitame, thaumatin, glycyrrgicacid and its salt, and neohesperidin dihydrochalcone, steviol glucoside type, neotame, aspartame - acetic syulpalm salt, tagatose, polyglycitol syrup, maltitol, lactitol, xylitol, erythritol and their mixture.
PURPOSE: A water-soluble silicate compound powder and a manufacturing method thereof are provided to soften skin due to fatigue recovery and skin-moisture effect by aiding and performing the cell activation. CONSTITUTION: A manufacturing method of a water-soluble silicate compound powder comprises the following steps. The quartz, tourmaline, and talc are pulverized and mixed with sodium carbonate(Na2CO3). The pulverized compound is maintained at a melting furnace with 1,650 degree Celsius for 24 hour to compose silicate mixed melted compound. The residues floating on the top of the silicate compound are removed. The silicate compound with removed residue is cooled at a room temperature for 12 hours. The cooled silicate compound is pulverized to manufacture the silicate compound powder.
The supplement (Mind Master) were custom prepared and donated by LR Healthy and Beauty Systems LTD. The supplement contained per 80ml, aloe barbadensis miller gel (USA/Mexico 36%), grape juice, Polygonum cuspidatum extract (that contain 10% resveratrol), green tea extract, 1.1 mg vitamin B1 (100% RDA), 2.5 µg vitamin B12 (100% RDA), 12 mg vitamin E (α - ΤΕ) (100% RDA), coenzyme Q10, 200 µg folic acid (100% RDA), ascorbic acid, 27.5 µg selenium (100% RDA), 4.2 mg iron (100% RDA).
The United States has a higher rate of unintended pregnancy than Canada or any other developed nation in Europe. Hormonal contraception is the most common method of contraception used in this country. Perfect use can lead to failure rates as low as 0.1% per year. Actual failure rates are much higher, often due to non-compliance with contraception use. Several recent studies have examined the "Quick Start", or initiation of hormonal contraception (OCPs and patch) in front of the provider while still at the clinic, regardless of time in the cycle. These studies have shown that women who placed the first patch in the clinic were more likely to continue the patch into the second month. Women who are seen in clinics for a therapeutic abortion (TAB) are often at extremely high risk for another unintended/unwanted pregnancy. If compliance in patch use could be improved in this group of women, unintended/unwanted pregnancy rates could be reduced. One concern about the "Quick Start" technique is that women may have already ovulated or conceived when the patch is initiated mid-cycle. In the post-abortal setting, this is not a concern. Applying the "Quick Start" technique to post-abortion patients and having women place the first patch while still in the clinic after their abortion may improve compliance and continuation of patch use.

This is a prospective, randomized, controlled trial in post-abortal women, and will last approximately 24 months. All of the study subjects will receive a month's worth of the patch and a one-year prescription after their TAB. The women in the immediate start arm will then place their first patch in the clinic, observed by clinic staff, before leaving. The controls will be instructed to place the first patch on the first Sunday following their abortion. All subjects will receive the same medication with the only difference being the timing of initiation of the patch. Measurements of continuation will be determined by telephone interviews administered at two and six months after the subjects' abortion.
BACKGROUND: Obesity and internalising disorders, including depression and anxiety, often co-occur. There is evidence that familial confounding contributes to the co-occurrence of internalising disorders and obesity in adults. However, its impact on this association among young people is unclear. Our study investigated the extent to which familial factors confound the association between internalising disorders and obesity in adolescents and young adults.
SUBJECTS/METHODS: We used a matched co-twin design to investigate the impact of confounding by familial factors on associations between internalising symptoms and obesity in a sample of 4018 twins aged 16 to 27 years.
RESULTS: High levels of internalising symptoms compared to low levels increased the odds of obesity for the whole cohort (adjusted odds ratio [AOR] = 3.1, 95% confidence interval [CI]: 1.5, 6.8), and in females (AOR = 4.1, 95% CI 1.5, 11.1), but not in males (AOR = 2.8 95% CI 0.8, 10.0). We found evidence that internalising symptoms were associated with an increased between-pair odds of obesity (AOR 6.2, 95% CI 1.7, 22.8), using the paired analysis but not using a within-pair association, which controls for familial confounding. Sex-stratified analyses indicated high internalising symptoms were associated with increased between-pair odds of obesity for females (AOR 12.9, 95% CI 2.2, 76.8), but this attenuated to the null using within-pair analysis. We found no evidence of between or within-pair associations for males and weak evidence that sex modified the association between internalising symptoms and obesity (likelihood ratio test p = 0.051).
CONCLUSIONS: Some familial factors shared by twins confound the association between internalising symptoms and obesity in adolescent and young adult females. Internalising symptoms and obesity were not associated for adolescent and young adult males. Therefore, prevention and treatment efforts should especially address familial shared determinants of obesity, particularly targeted at female adolescents and young adults with internalising symptoms and those with a family history of these disorders.
A processor-controlled, energy-based therapy apparatus includes a device configured to provide therapeutic energy to a patient and a processor that controls the output of the device. The output of the device is based on output profiles programmed into the processor. The output profiles include a therapeutic energy output profile and a ramp-up energy profile. The therapeutic energy output profile includes a desired target energy level and a therapeutic duration for controlling the output of the device during a therapeutic period. The ramp-up energy output profile includes an initial treatment energy level and a ramp-up duration for controlling the output of the device during a ramp-up period. The energy output specified by the ramp-up energy output profile incrementally increases over the ramp-up duration as a function of the desired target energy level and the ramp-up duration.
The present invention relates generally to a method for the treatment and/or prophylaxis of conditions arising from or otherwise associated with aberrations in hormone signalling. The present invention further provides an animal model useful for screening for agents capable of agonizing or antagonizing hormone signalling. More particularly, the present invention contemplates a method for the treatment and/or prophylaxis of conditions arising from or otherwise associated with aberrations in growth hormone signalling. The present invention further comprises a genetically modified animal. More particularly, the animals are genetically modified such that they have altered growth hormone signalling. The genetically modified animals of the present invention range from laboratory animals useful inter alia for animal models for studying hormone regulation and for the development of therapeutic protocols predicated, in part, on modulating hormone signalling to livestock animals. The latter may be manipulated for improved food production.
Of the 146 patients with NPC who were treated with LOQTORZI in combination with cisplatin and gemcitabine 7 (4.8%) were 65 years or older; there were no patients 75 years and older. Clinical studies of LOQTORZI in combination with cisplatin and gemcitabine did not include a sufficient number of patients aged 65 years and over with NPC to determine whether they respond differently from younger patients.

Of the 851 patients with tumor types including nasopharyngeal carcinoma or other types of tumors from the safety pool treated with LOQTORZI as a single agent, 171 (20%) patients were 65 years or older and 13 (1.5%) patients were 75 years and older. No overall differences in safety were observed between elderly patients and younger patients [see Adverse Reactions (6.1)].

Of the 190 patients with NPC treated with LOQTORZI as single agent, 10 (5%) patients were 65 years or older; there were no patients 75 years and older. Clinical studies of LOQTORZI did not include sufficient numbers of patients aged 65 years and over with NPC to determine whether they respond differently from younger patients.
Patients with a history of intestinal malabsorption (n=10) and healthy volunteers (n=10); (of both sexes and all ethnicities) will be recruited in this randomized double-blind crossover study. All subjects will be prescreened for 25(OH)D levels to include subjects with 25(OH)D\<30 ng/ml. The subjects will be randomized to receive a single oral dose of 900 µg of either vitamin D3 or 25(OH)D3. Blood samples will be taken at baseline and at 2,4,6,8,12 hours and days 1,2,3, 7 and 14. After a washout period of at least 14 days (2 weeks) the subjects will receive in a double blinded manner a single oral dose of 900 µg of either 25(OH)D3 or vitamin D3 (depending on which one they took in the randomization) any time after the washout. Blood samples will be taken at baseline and at 2,4,6,8,12 hours and days 1,2,3,7, 14.

Serum levels of calcium, phosphorus, albumin, creatinine, intact parathyroid hormone (iPTH) will be obtained at baseline and at day 14 (or within a reasonable time if unable to come in on the exact day). Vitamin D and 25(OH)D will be determined on all the blood samples collected at the various times.
Hydrogels are extensively utilized in the fields of electronic skin, environmental monitoring, biological dressings due to their excellent flexibility and conductivity. However, traditional hydrogel materials possess drawbacks such as environmental toxicity, low strength, poor stability, and water loss deactivation, which limited its frequent applications. Here, a flexible conductive hydrogel called wood-based DES hydrogel (WDH) with high strength, high adhesion, high stability, and high sensitivity was successfully synthesized by using environmentally friendly lignocellulose as skeleton and deep eutectic solvent as matrix. The strength of WDH prepared from lignocellulose framework is approximately 50 times higher than poly deep eutectic solvent hydrogel, and about 4.5 times higher than that prepared from cellulose skeleton. The WDH exhibits stable adhesion to most common materials and demonstrates exceptional dimensional stability. Its conductivity remains unaffected by water, even after prolonged exposure to air, maintaining a value of 0.0245 S/m. The anisotropy inherent in the system results in three distinct linear sensing intervals for WDH, exhibiting a maximum sensitivity of 5.45. This paper verified the advantages of lignocellulose framework in improving the strength and stability of hydrogels, which provided a new strategy for the development of sensor materials.
An aqueous composition comprising: i) At least 1 weight percent of a surfactant or mixture thereof. ii) A silicone in quantities of from 0.1 to 8 weight percent of the composition and having a minimum average particle size above 2 microns. iii) A hydrocarbonaceous material in quantities of from 0.1 to 8 weight percent of the composition. iv) A cationic polymer in quantities of from 0.02 to 1 weight percent of the composition. v) A combination of a polyacrylate thickening polymer and an acrylate/methacrylate copolymer wherein the ester group of the methacrylate is alkyl of 12 to 20 carbon atoms, the alkyl having 14 to 26 ethoxy groups and the acrylate is one or more monomers of acrylic acid, methacrylic acid or one of their simple esters in quantities sufficient to provide both viscosity and visual phase stabilization.  The polyacrylate is 0.5 to 2.0 weight percent of he composition and the acrylate methacrylate copolymer is 0.1 to 1.0 weight percent of the composition. vi) The balance water. Also described is an aqueous composition comprising: i) A skin cleansing amount of a surfactant or mixture thereof. ii) A silicone in quantities of from 0.1 to 8 weight percent of the composition. iii) A hydrocarbonaceous material in quantities of from 0.4 to 8 weight percent of the composition. iv) A cationic polymer in quantities of from 0.02 to 1 weight percent of the composition. v) A combination of a polyacrylate thickening polymer and an acrylate/methacrylate copolymer wherein the ester group of the methacrylate is alkyl of 12 to 20 carbon atoms, the alkyl having 14 to 26 ethoxy groups and the acrylate is one or more monomers of acrylic acid, methacrylic acid or one of their simple esters in quantities sufficient to provide both viscosity and visual phase stabilization. vi) The balance water.
A method of causing irreversible damage to stealth virus infected cells, based on light induced toxic photosensitivity of abnormal, aggregated, intracellular materials present in the infected cells. The method of the present application specifically relates to the culturing of stealth viruses from an infected subject and determining the presence in the stealth virus infected culture of auto-fluorescent material. Auto-fluorescent material can also be found in cultures of bacteria that are infected with the patient's stealth virus. The cultured stealth virus infected cells are to be further tested for susceptibility to the cellular destructive effect of light therapy given at various wavelengths that are not injurious to normal uninfected cells. The presence of auto-fluorescent material in the stealth virus culture and the demonstration that exposure to light can cause damage to stealth virus infected cells, form the basis of therapy for stealth virus infected patients and animals. The therapy comprises exposing infected cells within a patient to light at the wavelengths that were shown to cause damage to cultured virus infected cells. Light mediated therapy is especially applicable as therapy for stealth virus associated cancers in which the stealth virus isolated from the cancer patient can be shown to induce the formation of auto-fluorescent material.
Some participants, as a result of random selection, will be asked to participate in four, 45-minute sessions that will occur on four separate days while on the Inpatient Psychiatric Unit (IPU). These four sessions are in addition to the standard IPU treatment and are experimental. These four sessions will include mindfulness meditation practice and education, creating a Crisis Response Plan, and a brief introduction into self-compassion. As stated above, practicing mindfulness means focusing attention on what is occurring in the present moment in a non-judgmental way. The focus may be on what one is seeing or hearing or physical sensations, such as touch, as well as thoughts and emotions. Meditation is just sitting quietly and practicing mindful awareness.